Discussion Forums > Working Towards a Cure
Phase 3 Luspatercept Trial
Andy Battaglia:
Trials will be taking place in many different areas over a period of time, as patients are recruited. My educated guess is that we will see this drug on the market within 5 years.
CrazyPharm:
I have tried to enroll into the trials but was rejected the day it opened in my city because quota is already full. unbelievable... :huh.. i've been watching this drug ready to jump on the trial since its early phase 2 days. bummer i cant be a part i hope for a fast approval :wah
Andy Battaglia:
Check the recent post by Parin.
--- Quote ---bluebird bio is also moving forward with plans to initiate Northstar-3 (HGB-212), a Phase 3 trial of LentiGlobin drug product in patients with transfusion-dependent β-thalassemia with the β0/β0 genotype. This study will also be conducted under the new manufacturing process, and is expected to begin enrolling patients in 2017. The primary endpoint of this planned study is transfusion reduction.
--- End quote ---
Parin:
Thank you Andy for valuable information.
sofear:
Short question that came up: why are they never releasing detailed blood test results? Do they only mention the 'transfusion reduction' because that is also the current goal for their studies? I think it would be very helpful to see which effects the drug has on many other blood values and therefore on the body as a whole.
Navigation
[0] Message Index
[#] Next page
[*] Previous page
Go to full version